BriaCell Therapeutics Corp. Files 8-K: Material Agreement & Equity Sales
Ticker: BCTXZ · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1610820
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K detailing a material definitive agreement, unregistered equity sales, and other events.
AI Summary
On December 11, 2024, BriaCell Therapeutics Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for BriaCell Therapeutics, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- December 11, 2024 (date) — Earliest event reported
- Ansell Capital Corp. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by BriaCell Therapeutics Corp. on December 11, 2024?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold on an unregistered basis by BriaCell Therapeutics Corp.?
The filing mentions 'Unregistered Sales of Equity Securities' and lists 'BCTX:CommonSharesNoParValueMember' and 'BCTX:WarrantsToPurchaseCommonSharesNoParValueMember' as associated with December 11, 2024, suggesting common shares and warrants were involved.
What is the primary business of BriaCell Therapeutics Corp. according to the filing?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]'.
When was BriaCell Therapeutics Corp. formerly known as Ansell Capital Corp.?
The date of the name change from Ansell Capital Corp. to BriaCell Therapeutics Corp. was June 13, 2014.
What is the fiscal year end for BriaCell Therapeutics Corp.?
The fiscal year end for BriaCell Therapeutics Corp. is July 31.
Filing Stats: 1,184 words · 5 min read · ~4 pages · Grade level 10.9 · Accepted 2024-12-13 16:15:31
Key Financial Figures
- $0.75 — at a combined public offering price of $0.75 per Unit. The Warrants have an exercise
- $0.9375 — The Warrants have an exercise price of $0.9375 per share, are immediately exercisable
- $0 — ve's Warrants have an exercise price of $0.9375, are immediately exercisable and e
- $5.55 million — eeds from the Offering of approximately $5.55 million. The Company intends to use the gross p
Filing Documents
- form8-k.htm (8-K) — 53KB
- ex1-1.htm (EX-1.1) — 704KB
- ex4-1.htm (EX-4.1) — 124KB
- ex4-2.htm (EX-4.2) — 151KB
- ex5-1.htm (EX-5.1) — 19KB
- ex5-2.htm (EX-5.2) — 15KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-2.htm (EX-99.2) — 17KB
- ex99-3.htm (EX-99.3) — 15KB
- ex5-1_001.jpg (GRAPHIC) — 9KB
- ex5-1_002.jpg (GRAPHIC) — 12KB
- ex5-1_003.jpg (GRAPHIC) — 5KB
- ex5-2_001.jpg (GRAPHIC) — 7KB
- ex5-2_002.jpg (GRAPHIC) — 5KB
- 0001493152-24-049999.txt ( ) — 1610KB
- bctx-20241211.xsd (EX-101.SCH) — 4KB
- bctx-20241211_def.xml (EX-101.DEF) — 29KB
- bctx-20241211_lab.xml (EX-101.LAB) — 36KB
- bctx-20241211_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams December 13, 2024 William V. Williams President and Chief Executive Officer